• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Orphan drugs: Indian perspective.罕见病药物：印度视角
Indian J Pharmacol. 2017 Jul-Aug;49(4):267-269. doi: 10.4103/ijp.IJP_646_17.
2
The study of drugs for rare disorders: harnessing research contributions by Canadian academic institutions.罕见病药物研究：利用加拿大学术机构的研究贡献
J Popul Ther Clin Pharmacol. 2014;21(1):e47-55. Epub 2014 Feb 23.
3
The role of academic institutions in the development of drugs for rare and neglected diseases.学术机构在罕见病和被忽视疾病药物研发中的作用。
Clin Pharmacol Ther. 2012 Aug;92(2):193-202. doi: 10.1038/clpt.2012.83. Epub 2012 Jul 4.
4
Orphan drug designation and development in Japan: 25 years of experience and assessment.日本的孤儿药认定与研发：25年的经验与评估
Nat Rev Drug Discov. 2021 Dec;20(12):893-894. doi: 10.1038/d41573-021-00045-3.
5
Neuromuscular disorders: orphan diseases deserve attention.
Lancet Neurol. 2006 Jan;5(1):13-4. doi: 10.1016/S1474-4422(05)70263-5.
6
[Orphan drugs. Drugs for treatment of rare diseases].[孤儿药。用于治疗罕见病的药物]
Med Monatsschr Pharm. 2004 Aug;27(8):256-9.
7
Drug labels: a flawed source of data for studying orphan drug approvals.药品标签：用于研究罕见病药物批准情况的有缺陷的数据来源。
Clin Pharmacol Ther. 2012 Dec;92(6):694; author reply 695. doi: 10.1038/clpt.2012.166. Epub 2012 Oct 17.
8
Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?罕见肺部疾病与孤儿药：我们现状如何，又将何去何从？
Eur Respir Rev. 2015 Sep;24(137):375-7. doi: 10.1183/16000617.0051-2015.
9
The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study.印度孤儿药组织的工作、目标、挑战、成就和建议：基于访谈的研究。
Orphanet J Rare Dis. 2019 Nov 4;14(1):241. doi: 10.1186/s13023-019-1224-0.
10
Crafting a robust business model for orphan drug development.为罕见病药物研发打造强大的商业模式。
Hum Gene Ther. 2011 Jul;22(7):781-3. doi: 10.1089/hum.2011.2511.

引用本文的文献

1
Navigating health policies and programs in India: exploring opportunities to improve rare disease management and orphan drug research.在印度，探索卫生政策和项目：改善罕见病管理和孤儿药研究的机会。
Orphanet J Rare Dis. 2024 Nov 29;19(1):446. doi: 10.1186/s13023-024-03377-6.
2
Assessment of the availability of repurposed orphan drugs in India.印度重新利用的罕见病药物可及性评估。
PLOS Glob Public Health. 2023 Sep 27;3(9):e0001498. doi: 10.1371/journal.pgph.0001498. eCollection 2023.
3
Review: Understanding Rare Genetic Diseases in Low Resource Regions Like Jammu and Kashmir - India.综述：了解印度查谟和克什米尔等资源匮乏地区的罕见遗传病
Front Genet. 2020 Apr 30;11:415. doi: 10.3389/fgene.2020.00415. eCollection 2020.
4
Genomics of rare genetic diseases-experiences from India.罕见遗传病的基因组学：来自印度的经验。
Hum Genomics. 2019 Sep 25;14(1):52. doi: 10.1186/s40246-019-0215-5.
5
The role of patient organizations in the rare disease ecosystem in India: an interview based study.患者组织在印度罕见病生态系统中的作用：基于访谈的研究。
Orphanet J Rare Dis. 2019 May 29;14(1):117. doi: 10.1186/s13023-019-1093-6.

本文引用的文献

1
Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries.罕见病药物的可及性：35个国家的立法、法规及政策综合综述
PLoS One. 2015 Oct 9;10(10):e0140002. doi: 10.1371/journal.pone.0140002. eCollection 2015.
2
Organization for rare diseases India (ORDI) - addressing the challenges and opportunities for the Indian rare diseases' community.印度罕见病组织（ORDI）——应对印度罕见病群体面临的挑战与机遇。
Genet Res (Camb). 2014 Aug 13;96:e009. doi: 10.1017/S0016672314000111.
3
Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives.亚洲的罕见病、孤儿药及其监管：现状与未来展望
Intractable Rare Dis Res. 2012 Feb;1(1):3-9. doi: 10.5582/irdr.2012.v1.1.3.
4
Clinical trials in rare disease: challenges and opportunities.罕见病的临床试验：挑战与机遇
J Child Neurol. 2013 Sep;28(9):1142-50. doi: 10.1177/0883073813495959.
5
Rare diseases and orphan drugs.罕见病与孤儿药。
Nat Rev Drug Discov. 2012 Mar 30;11(4):267-8. doi: 10.1038/nrd3654.
6
Orphan drug development: an economically viable strategy for biopharma R&D.孤儿药开发：生物制药研发的经济可行策略。
Drug Discov Today. 2012 Jul;17(13-14):660-4. doi: 10.1016/j.drudis.2012.02.005. Epub 2012 Feb 17.

Orphan drugs: Indian perspective.

作者信息

Kumar Harish, Sarma Phulen, Medhi Bikash

机构信息

Department of Pharmacology, PGIMER, Chandigarh, India.

出版信息

Indian J Pharmacol. 2017 Jul-Aug;49(4):267-269. doi: 10.4103/ijp.IJP_646_17.

DOI:10.4103/ijp.IJP_646_17
PMID:29326485
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5754932/
Abstract
摘要